Developing Novel Integrin-Based Therapeutics DECEMBER 2025 © 2025 PLIANT THERAPEUTICS Disclaimers This presentation has been prepared by Pliant Therapeutics, Inc. ("we," "us," "our," "Pliant" or the "Company"). The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and this presentation shall not under any circumstances create an implication that th ...

Core Insights - Pliant Therapeutics, Inc. is participating in the Piper Sandler 37th Annual Healthcare Conference from December 2 to 4, 2025 [1] - Key executives including Bernard Coulie, M.D., Ph.D., Keith Cummings, M.D., and Éric Lefebvre, M.D. will engage in a fireside chat on December 4, 2025, at 12:30 p.m. Eastern Time [2] - A live webcast of the fireside chat will be available, with a replay archived for 90 days on Pliant's website [3] Company Overview - Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on integrin-based therapeutics [4] - The lead program, PLN-101095, is a small molecule dual-selective inhibitor targeting αvß8 and αvß1 integrins for solid tumor treatment [4] - Pliant has regulatory clearance for a Phase 1 study of PLN-101325, a monoclonal antibody agonist targeting integrin α7β1 for muscular dystrophies [4] - The company is also engaged in preclinical research on tissue-specific delivery and internalization of drug payloads using integrin receptor-binding molecules [4]

Core Viewpoint - Pliant Therapeutics has discontinued the development of bexotegrast for idiopathic pulmonary fibrosis (IPF) following an unfavorable risk-benefit profile identified in the BEACON-IPF Phase 2b/3 clinical trial [1][3][5] Group 1: Clinical Trial Results - The BEACON-IPF trial was a randomized, double-blind, placebo-controlled study that revealed an imbalance in IPF-related adverse events, leading to its voluntary discontinuation [2] - Analysis of safety and efficacy data indicated that bexotegrast at doses of 160 mg and 320 mg increased the risk of adverse events related to IPF progression, with an average time to disease progression of 33 weeks for treated participants [3] - At Week 12, the 160 mg and 320 mg treatment groups showed improvements in forced vital capacity (FVC) decline of 72 mL (p<0.05) and 46 mL (p>0.05) respectively, while at Week 24, improvements were 58 mL (p>0.05) and 8 mL (p>0.05) respectively compared to placebo [4] Group 2: Future Development Plans - The company continues to enroll patients in a Phase 1 trial for PLN-101095, a dual-selective inhibitor targeting solid tumors resistant to immune checkpoint inhibitors, with interim results showing 50% confirmed partial responses at the highest dose tested [6] - Pliant's drug discovery platform includes over 15,000 integrin binding molecules and aims to support early-stage programs across multiple disease areas, focusing on tissue-specific delivery mechanisms [7][9]